FDA awards contract to organs-on-chip lab for radiation countermeasures

The U.S. Food and Drug Administration has awarded a $5.6 million contract to Harvard University’s Wyss Institute for Biologically Inspired Engineering to apply its breakthrough organs-on-chips technology to assess medical countermeasures for treating acute radiation syndrome (ARS), also known as radiation sickness.

Organs-on-chips are microchips that mimic the functions of and tissue structures present in living organs, such as the lung, heart and intestine. The technology replicates the interactions between the living tissues within human organs on chips the size of a thumb drive. Under the contract, Wyss Institute scientists will develop models of radiation damage in lung, gut and bone marrow organs-on-chips and then use these models to test candidate medical countermeasures.

“Organs-on-chips technology represents the kind of transformational change in the way products are evaluated that is critical to advancing regulatory science, the science underpinning all FDA regulatory decisions,” said Luciana Borio, M.D., the FDA’s assistant commissioner for counterterrorism policy. “It holds enormous promise for improving our understanding of new medical countermeasures, particularly when it is unethical or unfeasible to conduct efficacy studies in humans; and when available animal models have limited use in accurately predicting human response.”

The FDA plays a critical role in protecting the United States from chemical, biological, radiological, nuclear, and emerging infectious disease threats. FDA’s responsibility is to ensure that medical countermeasures—such as drugs, vaccines, and diagnostic tests—to counter these threats are safe, effective, and secure.
ARS, an illness affecting a combination of organs, occurs when the body receives a high dose of radiation over a short period of time—as would be expected to occur after a nuclear or radiological incident. The first symptoms of ARS typically are nausea, vomiting and diarrhea. These symptoms will start within minutes to days after the exposure, will last for minutes up to several days, and may come and go. Then the person usually looks and feels healthy for a short time, after which he or she will become sick again with loss of appetite, fatigue, fever, nausea, vomiting, diarrhea, and possibly even seizures and coma. This seriously ill stage may last from a few hours up to several months.

Developing medical countermeasures to treat ARS is a high-priority for the U.S. government, but presents complex scientific challenges. ARS may involve many organ systems, which makes it hard to study candidate medical countermeasures that target the radiation effects on one specific organ system in animal models. Also, certain candidate medical countermeasures cannot be effectively studied in animal models because their activity is specific to humans. The Wyss Institute’s organs-on-chips offer a unique opportunity to potentially address some of these challenges.

The technology will provide a capability to evaluate candidate medical countermeasures for ARS within the specific context of a target human organ system, which could yield valuable information for facilitating development.

The Wyss Institute contract was awarded through a Broad Agency Announcement (BAA) for the Advanced Research and Development of Regulatory Science, in the area of Supporting Medical Countermeasures Development to Protect National Health and Security.

1 COMMENT

  1. It was amazing to hear of the potential that Organs-on-chips had in the scientific field but now that the FDA has awarded a contract and funding to Harvard’s Wyss Institute the possibilities present in this technology are becoming a reality. Due to recent events such as the possible biological warfare going on in the middle east and even seen in historical events such as Hiroshima, it is vital for scientists to be on top of treatments for things such as acute radiation syndrome . Organs-on-chips allows scientists to develop medicines to counter act radiation sickness and the threats of biological warfare. Along with the importance of finding ways to treat ARS and such illnesses, organs-on-chips allows faster and more comprehensive research and development of drugs. Being able to test things that were possibly unethical or dangerous to test on humans. This technology has really made so many developments possible and I am excited to see what it will accomplish in the future.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.